
Dimerix shares plunged 35–40% amid heavy selling and uncertainty around clinical updates, worsened by weak biotech sentiment. Further downside depends on results and the funding outlook, though volatility in early-stage biotech stocks suggests a potential for sharp rebounds.

This report highlights three high-yield ASX dividend stocks across different industries, offering strong income and upside potential over the next 6–12 months, backed by durable competitive advantages, profitable business models, and valuations that appear attractive relative to their long-term growth prospects.

Nuix remains in a weak downtrend despite a bounce toward ~$1.5. The stock is consolidating between ~$1.1–$1.5, showing stabilisation but no confirmed bottom. A breakout above resistance is needed, with risks still skewed to the downside.

Lodestar Minerals has surged ~129% YTD after a breakout to ~$0.028, with potential upside toward $0.03–$0.04 if momentum continues. However, as an early-stage explorer, gains are likely event-driven and volatile, with sustainability dependent on exploration success.

Lynas Rare Earths (ASX: LYC) recently broke its short-term uptrend due to weak Q3 production, facility outages, and expansion costs. Technical analysis indicates strong downside momentum, with the next major support zone sitting lower around the $16.00–$16.23 level.

Meeka Metals faces selling pressure near key support after a volatile year, amid operational challenges and cautious sentiment. As it transitions to production at Murchison, investors are watching whether support holds or signals further downside despite long-term growth potential.